SOCIUM Inc. and Huaxi Hospital of Sichuan University have decided to conduct an investigator-initiated clinical trial of SO-002, a drug candidate for the treatment of amyotrophic lateral sclerosis (ALS)

AI drug discovery venture that takes on the challenge of overcoming “unmet medical needs, SOCIUM Inc.’s paper was published in The Journal of Biomedical Research

株式投資型クラウドファンディングの実施 及び オンライン事業説明会開催のお知らせ 

Announcement of a Strategic Alliance for the Development of Drugs for the Treatment of Rare Diseases in China

Our Paper on Phosphorylation Analysis Accepted through Collaboration with Nanjing Medical University School of Pharmacy (China)

Exhibit at “Japan Healthcare Venture Summit 2023”